+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro activity of ciprofloxacin (Bay o 9867)



In vitro activity of ciprofloxacin (Bay o 9867)



Antimicrobial Agents and ChemoTherapy 24(4): 568-574



The in vitro activities of ciprofloxacin (Bay o 9867) and seven comparative antimicrobial agents against 664 aerobic and facultatively anaerobic bacterial isolates were studied. Minimal inhibitory concentrations (MICs) of ciprofloxacin were less than or equal to 2 micrograms/ml for Enterobacteriaceae, less than or equal to 8 micrograms/ml for nonfermentative gram-negative bacilli, less than or equal to 4 micrograms/ml for gram-positive cocci, less than or equal to 0.03 micrograms/ml for Aeromonas hydrophila and Pasteurella multocida, and less than or equal to 1 microgram/ml for Listeria monocytogenes. MICs for multi-drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa were less than or equal to 4 micrograms/ml. Ciprofloxacin MICs were consistently 0 to 4 (usually 2 to 3) dilution steps lower than those of a related drug, norfloxacin (P less than 0.0001). For most species, they were lower than MICs of cefotaxime, aztreonam, theinamycin, mezlocillin, trimethoprim-sulfamethoxazole, and amikacin. With all eight drugs, increasing the inoculum size by 100-fold had a variable effect on MICs which was species related. Ciprofloxacin is a potent broad-spectrum new antimicrobial agent.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 005645454

Download citation: RISBibTeXText

PMID: 6228192

DOI: 10.1128/AAC.24.4.568


Related references

In vitro activity of ciprofloxacin bay o 9867 against pulmonary pathogens. Abstracts of the Annual Meeting of the American Society for Microbiology 87: 3, 1987

Ciprofloxacin (BAY O 9867). Comparative in vitro activity study. Microbiologia Espanola 37(3-4): 73-79, 1984

The in vitro activity of ciprofloxacin bay o 9867 against clinical isolates from urinary tract infections. Nishinihon Journal of Urology 49(5): 1331-1338, 1987

Comparison of the in vitro activity of ciprofloxacin (Bay o 9867) and norfloxacin against gastrointestinal tract pathogens. European Journal of Clinical Microbiology 3(4): 367-367, 1984

In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867). Antimicrobial Agents and ChemoTherapy 26(5): 785-786, 1984

Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae. Infection 11(6): 326-328, 1983

Comparative evaluation of the antimycobacterial activity of ciprofloxacin bay o 9867 utilizing the bactec system and standard macrobroth dilution susceptibility tests. Abstracts of the Annual Meeting of the American Society for Microbiology 86: 390, 1986

Pharmacokinetics of ciprofloxacin bay o 9867 in the uterus and adnexa. Gynaekologische Rundschau 25(2 SUPPL): 149-151, 1985

Ciprofloxacin bay o 9867 in bacterial respiratory tract infections. Giornale Italiano delle Malattie del Torace 43(4): 289-292, 1989

Bay o 9867 (ciprofloxacin) in the treatment of urinary tract infections in elderly patients. Rivista Europea Per le Scienze Mediche E Farmacologiche 10(4): 333-339, 1988

Clinical study of ciprofloxacin bay o 9867 in the treatment of prostatitis and acute epididymitis. Nishinihon Journal of Urology 49(2): 673-690, 1987

Twice daily therapy of bacterial bronchitis with ciprofloxacin bay 9867 a new quinolone antibiotic. American Review Of Respiratory Disease Suppl: A126, 1986

High performance liquid chromatography of bay o 9867 ciprofloxacin in serum samples. Journal of Liquid Chromatography 8(3): 555-562, 1985

Comparison of clinical efficacy of ciprofloxacin (CPFX, BAY o 9867) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Ciprofloxacin, Research Group for Infectious Enteritis. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 62(4): 322-339, 1988

Comparative study of ciprofloxacin bay o 9867 and norfloxacin in the treatment for acute lacunar tonsillitis. Otologia Fukuoka 33(2): 312-336, 1987